CTOs on the Move

Kaken Pharmaceuticals

www.kaken.com

 
Kaken Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.kaken.com
  • 245 Park Ave New York
    New York, NY USA 10167
  • Phone: 212.372.8910

Executives

Name Title Contact Details

Similar Companies

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.

Koronis Pharmaceuticals

Koronis Pharmaceuticals is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Specialty Flooring Systems Inc

Specialty Flooring Systems Inc is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Church Street Health Management

"Our company`s promise is in our name - CSHM - Committed to Smiles and a Healthy Mouth. Our mission is to ensure access to quality, professional dental care for low-income, underserved families and those seeking comprehensive care. Our dental centers are creating access to dental health services for these families – and especially their children – who are often least able to afford care."

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.